Literature DB >> 3597714

Natural killer (NK)-cell activity in sorted subsets of peripheral blood mononuclear cells from patients with severe combined immunodeficiency.

R J ten Berge, P T Schellekens, A Budding-Koppenol, L J Dooren, J M Vossen.   

Abstract

Natural killer-cell activity for K562 target cells was measured in 13 patients with severe combined immunodeficiency before bone marrow transplantation. Both unseparated peripheral blood mononuclear cells and sorted cell subsets (B73.1 positive, B73.1 negative, OKT3 positive, OKT3 negative) were tested. Heterogeneity of natural killer-cell activity was observed, the level of which did not correlate with the usual subdivision of severe combined immunodeficiency, as defined by a scientific group on immunodeficiency for the WHO. In those patients in whom natural killer-cell activity was observed in unseparated cells, testing of this function in sorted cell subsets revealed some unexpected findings. In three of four patients, B73.1-negative cells showed remarkable natural killer-cell activity. In addition, in one of these patients, no activity was observed in the B73.1-positive cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3597714     DOI: 10.1007/bf00915724

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  17 in total

1.  Severe combined immunodeficiency with natural killer-cell predominance: abrogation of graft-versus-host disease and immunologic reconstitution with HLA-identical bone marrow cells.

Authors:  L J Sindel; R H Buckley; S E Schiff; F E Ward; G H Mickey; A T Huang; C Naspitz; H Koren
Journal:  J Allergy Clin Immunol       Date:  1984-06       Impact factor: 10.793

2.  Rapidly expanded activated human killer cell clones have strong antitumor cell activity and have the surface phenotype of either T gamma, T-non-gamma, or null cells.

Authors:  R J van de Griend; B A van Krimpen; C P Ronteltap; R L Bolhuis
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

3.  Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line.

Authors:  J R Ortaldo; R K Oldham; G C Cannon; R B Herberman
Journal:  J Natl Cancer Inst       Date:  1977-07       Impact factor: 13.506

4.  Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. II. Studies of B73.1 antibody-antigen interaction on the lymphocyte membrane.

Authors:  B Perussia; O Acuto; C Terhorst; J Faust; R Lazarus; V Fanning; G Trinchieri
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

5.  Primary immunodeficiency diseases. Report prepared for the WHO by a scientific group on immunodeficiency.

Authors: 
Journal:  Clin Immunol Immunopathol       Date:  1983-09

6.  Characterization of two subsets of human T gamma cells.

Authors:  R J van de Griend; I ten Berge; H J Tanke; D Roos; P T Schellekens; C J Melief; W P Zeijlemaker; A Astaldi
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

7.  Induction of proliferation in vitro of resting human natural killer cells: expression of surface activation antigens.

Authors:  L London; B Perussia; G Trinchieri
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

8.  Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1.

Authors:  B Perussia; S Starr; S Abraham; V Fanning; G Trinchieri
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

9.  Severe combined immunodeficiencies, primary T-cell defects and DiGeorge syndrome in humans: characterization by monoclonal antibodies and natural killer cell activity.

Authors:  M C Sirianni; L Businco; R Seminara; F Aiuti
Journal:  Clin Immunol Immunopathol       Date:  1983-09

10.  Human natural killer cells isolated from peripheral blood do not rearrange T cell antigen receptor beta chain genes.

Authors:  L L Lanier; S Cwirla; N Federspiel; J H Phillips
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.